- trying to bring together two communities (ipr experts/competition experts; national competition authorities/national ip offices)
- ipr-competition not antagonistic
- well-balanced ip also very important
-- outcome envisaged: no formal conclusions or recommendations
-- new division on ip/competition established
-- technical assistance (already requested by Syria)
- iprs are not monopolies, they are not a "necessary evil" but, and foremostly, a differentiation/identification tool (i.e. not only about creations and inventions)
-- insofar, at the very core of competition and rivarly,
-- not easy; necessary trials and errors, institutional/legal experiments, picking out the efficient solutions
- difference between an abuse of ip that results into anticompetitive effects and another which does not (reference to a case concerning a patent for irradiating food stuff increasing its vitamin c content and the legal issues thereof involving the important principle of access to health)
- TRIPs allows for a certain freedom in this area, but countries very often are not using it
-- but TRIPs leaves some questions unanswered (e.g., evaluative standards to anticompetitivess)
-- WIPO, WTO, OECD should provide some more help in this respect
-- collective guidelines could be helpful, based on enforcement experience, study and reflection
-- well designed ip systems already address (most) competition concerns internally (i.e., patentability criteria)
- TRIPs, articles 40, 31, 31.k, 8.2
-- art. 40.2 permissive rather than prescriptive (list non-exhaustive)
-- art. 31 (compulsory licences)
--- detailed conditions
--- protecting the legitimate interest of the right holder
-- art. 31.k (competition policy "shortcut"): "...use is permitted to remedy a practice determined after judicial or administrative process to be anti-competitive"
--- unanswered question:decision taken by the head of a national competition authority is an "administrative process"?
- clash of remedies possible
-- e.g. Microsoft
--- compulsory licence in the EU, "leak" across other jurisdictions
---- before deciding on remedies, possible repercussions should be carefully investigated
-- clusters of blocking patents
-- standards-reinforced patents
-- gene patents
-- grantbacks, but depending on circumstances
-- conflicts likely to be increasingly significant, also at the remedies level
--- NCAs likely to oppose "hard" convergence
- Recommendation 40 ("To request WIPO to intensify its cooperation on IP related issues with United Nations agencies, according to Member States’ orientation, in particular UNCTAD, UNEP, WHO, UNIDO, UNESCO and other relevant international organizations, especially the WTO in order to strengthen the coordination for maximum efficiency in undertaking development programs")
- Development Agenda as a major event at the WIPO
- in the 80's only 20 national competition authorities (from now on: NCAs), now more than 100 (many in developing countries)
- Competition Law and Policy (Programme)
-- background papers to Intergovernmental Expert Meetings
--- COMPETITION POLICY AND THE EXERCISE OF INTELLECTUAL PROPERTY RIGHTS (TD/B/COM.2/CLP/22/Rev.1)
-- technical assistance on demand
-- Peer Review on competition legislation(voluntary)
--- "model" advise on provisions impacting iprs
---- complementarity iprs/competition
---- different tools
---- exclusivities to stimulate innovation,
----- in case of market power, not prohibited per-se, but they could have anticompetitive effects
--- Chapter II, II (a) Scope of application: "goods, services or intellectual property"
-- UNCTAD's mandates in this field
--- Accra Accord
--- Rec. 40 Development Agenda (above)
--- WHO's Global Strategy and plan of action on public health, innovation and intellectual property (2008)
--- foster generic competition immediately after patent's expiry
--- create a competitive environment for generics
- iprs and competition not conflicting
- good competition policy, well run and designed provides for incentives to innovate
-- short-term not always central
- patent system to be procompetitive
-- room for disruptive innovation
-- role of venture capitalists
- both ip system and effective competition ideally provide for innovations
-- but iprs used in defensive (patent portfolio and patent deals) and strategic way
- IF too easy to obtain and enforce, high penalties
-- from a societal point of view, the same level of innovation could be obtained giving less away
-- very expensive for other firms
-- entry barriers high
-- R&D deterred
- IF ipr too difficult to obtain, penalties toothless
-- incentives inefficiently low
--- not worth to invest
-- complex design of secrecy
--- disclosure and diffusion insufficient from a societal perspective (forcep's example: invention non patented and kept secret)
-- iprs targeted because of their success
-- too low incentives, no licensing agreements
-- licensing as masquerade for cartels
-- standard organizations ambushed
-- patent surge, not only because of increased innovation
--- harm to competition?
--- innovation stifled?
-- courts, NCAs to "rebalance" this?
--- expertise needed to do this very high in the face of limited resources available
---- delays, risk of slowing down innovation (overkill)
-- Ip law needs fixing
--- some improvements, grant rates are coming down
- Actions
-- dialogue with patent agencies
-- OECD's role
--- reports
--- seminars, hearings, fora (see 2010 Global Forum on Competition)
-- licensing arrangements
--- most of them at least neutral from a comp policy perspective - technology transfer
--- grantbacks
---- positive: risk sharing, financing
---- negative: possibly in case of exclusive, severable improvements (follow-on innovations deterred)
-- patent pools
--- usually at least neutral
--- positive: complementary, essential iprs
--- negative: possibly when substitute iprs
---- market sharing; cover up for price agreements
---- foreclosure of third parties' technologies
-- "naked" unilateral refusal to license ip (not refusal + like in mergers)
--- OECD members: diverging answers
---- EU, compulsory licence as remedy
---- US, different philosophy
---- most members
----- compulsory licences generally not suitable
----- ip system not always effective
------- but importance of "working around" granted iprs
-- NCA stating licensing terms (e.g. fees) possibly acting as regulator and not as arbiter.
US Dep. of Justice, Antitrust Division
- complex issue
- technological innovations as primary driver of economic growth
- distinction between invention and innovation (inno a longer process)
- complementarity
- ip questions everywhere (enforcement, advocacy, business review letters)
-- within merger proceedings particularly difficult
- tools available
-- prior cases
-- guidelines
-- 2007 Report, Antitrust Enforcement and Intellectual Property Rights: Promoting Innovation and Competition, etc.
- coming next: joint public workshop (DoJ, FTC, US PTO) to Explore the Intersection of Patent Policy and Competition Policy and its Implications for Promoting Innovation
Evolution in the way of thinking about the interface ip/comp
- 70's patents often considered monopolies, licensing stifled
- 80's rule of reason, licensing seen positively as long as different factors of production are combined (other issue: transaction costs, prod costs, free riding)
- 1995 Guidelines
-- no special rules for iprs
-- patents not presumption of market power (Supreme Court agrees in 1996)
-- market power not enough
-- benefits of licensing
--- combination of productive assets
-- focus on certain restraints
-- counterfactual licensing analysis
--- potential comp
--- likely to decrease comp
--- reduction of incentives to innovate
---- but: much less practice sofar with socalled dynamic efficiencies (theoretical challenge)
-- per se area
- international convergence on the basis of an increasingly common economic approach
- ipr/comp: no real conflict, both promoting innovation
-- open markets a very good incentive for innovation
-- competition policy as an element of a broader legal framework for innovation
--- a market that rewards present innovation without stifling future innovation
- innovation can be very risky,
-- but differences according to the markets under consideration
--- patent, less important in software business (seen often by market participants as obstacles to
- strategic use of patents increased
--pharma sector
--- strategic, possibly anticompetitive
- "probabilistic patents", Shapiro (and Lemley)
-- patents as lottery tickets
- patent reform could take care of it ?
- standards setting
-- benefits, interoperability, etc
-- but risks of abuse of market power
--- de facto, formal
- Microsoft Europe
-- withholding the interoperability info (not an ip case as such: patents covering interoperability info "found" by MS very late in the proceeding)
-- innovation incentives much discussed in court proceedings
--- issue possibly exceptional because it has to do with interoperability
-- in substance not so different from the US Microsoft decision on remedies (also compulsory licence of interoperability info)
- Rambus